<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Radiol</journal-id><journal-id journal-id-type="iso-abbrev">Br J Radiol</journal-id><journal-id journal-id-type="pmc-domain-id">1897</journal-id><journal-id journal-id-type="pmc-domain">brjradiol</journal-id><journal-id journal-id-type="publisher-id">bjr</journal-id><journal-title-group><journal-title>The British Journal of Radiology</journal-title></journal-title-group><issn pub-type="ppub">0007-1285</issn><issn pub-type="epub">1748-880X</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4743575</article-id><article-id pub-id-type="pmcid-ver">PMC4743575.1</article-id><article-id pub-id-type="pmcaid">4743575</article-id><article-id pub-id-type="pmcaiid">4743575</article-id><article-id pub-id-type="pmid">26133222</article-id><article-id pub-id-type="doi">10.1259/bjr.20150163</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Full Paper</subject></subj-group><subj-group subj-group-type="collection"><subject>Genitourinary Tract</subject></subj-group></article-categories><title-group><article-title>Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging</article-title><alt-title alt-title-type="left-running-head">TY Jeon <italic toggle="yes">et al</italic></alt-title><alt-title alt-title-type="right-running-head">Therapeutic response evaluation to sorafenib in RCC xenografts by MRI</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jeon</surname><given-names initials="TY">T Y</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hathor97.jeon@samsung.com">hathor97.jeon@samsung.com</email></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Kim</surname><given-names initials="CK">C K</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="chankyokim@skku.edu">chankyokim@skku.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="JH">J-H</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jaehun1115.kim@samsung.com">jaehun1115.kim@samsung.com</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Im</surname><given-names initials="GH">G H</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="geunho.im@samsung.com">geunho.im@samsung.com</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="BK">B K</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bk1436.park@samsung.com">bk1436.park@samsung.com</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="JH">J H</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="junghee42.lee@samsung.com">junghee42.lee@samsung.com</email></contrib><aff id="aff1"><label><sup>1</sup></label><addr-line>Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</addr-line></aff><aff id="aff2"><label><sup>2</sup></label><addr-line>Department of Medical Device Management and Research, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea</addr-line></aff><aff id="aff3"><label><sup>3</sup></label><addr-line>Department of Radiology and Center for Molecular and Cellular Imaging, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Address correspondence to: Dr Chan Kyo Kim. E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="chankyokim@skku.edu">chankyokim@skku.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2015</year><string-date>September 2015</string-date></pub-date><pub-date pub-type="epub"><day>28</day><month>7</month><year>2015</year></pub-date><volume>88</volume><issue>1053</issue><issue-id pub-id-type="pmc-issue-id">264804</issue-id><elocation-id>20150163</elocation-id><history><date date-type="received"><day>23</day><month>2</month><year>2015</year><string-date>Received on February 23, 2015</string-date></date><date date-type="rev-recd"><day>8</day><month>6</month><year>2015</year><string-date>Revised on June 8, 2015</string-date></date><date date-type="accepted"><day>1</day><month>7</month><year>2015</year><string-date>Accepted on July 1, 2015</string-date></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2016</year></date></event><event event-type="pmc-live"><date><day>01</day><month>09</month><year>2016</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2016-09-01 00:14:25.850"><day>01</day><month>09</month><year>2016</year></date></event></pub-history><permissions><copyright-statement>&#169; 2015 The Authors. Published by the British Institute of Radiology</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>The Authors</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bjr.20150163.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="bjr.20150163.pdf"/><abstract><sec><title>Objective:</title><p>To investigate the feasibility of dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DWI) in monitoring early therapeutic response to sorafenib in renal cell carcinoma (RCC) xenograft models.</p></sec><sec><title>Methods:</title><p>Sorafenib (40&#8201;mg&#8201;kg<sup>&#8722;1</sup>) was administered orally to BALB/c nude mice (<italic toggle="yes">n</italic>&#8201;=&#8201;9) bearing subcutaneous tumours of human RCC ACHN xenografts. DCE-MRI and DWI were obtained 0, 1, 3 and 7 days after therapy, and DCE-MRI parameters (K<sup>trans</sup> and <italic toggle="yes">v</italic><sub>e</sub>) and apparent diffusion coefficient (ADC) values were calculated. Tumour size and volume changes were correlated with changes in DCE-MRI parameters or ADC values after therapy.</p></sec><sec><title>Results:</title><p>Following therapy, K<sup>trans</sup> showed a significant decrease over time (<italic toggle="yes">p</italic>&#8201;=&#8201;0.005), whereas <italic toggle="yes">v</italic><sub>e</sub> did not demonstrate significant changes between time points (<italic toggle="yes">p</italic>&#8201;=&#8201;0.97). ADC values showed a progressive increase over time (<italic toggle="yes">p</italic>&#8201;=&#8201;0.004). Compared with pre-therapy, K<sup>trans</sup> showed a significant decrease after 3 days of therapy (<italic toggle="yes">p</italic>&#8201;=&#8201;0.039), and ADC values increased significantly after 7 days (<italic toggle="yes">p</italic>&#8201;=&#8201;0.039). Tumour size and volume did not show significant changes during 7 days. Tumour size and volume changes were not associated with changes in DCE-MRI parameters or ADC values.</p></sec><sec><title>Conclusion:</title><p>DCE-MRI and DWI may show early physiological changes within 1 week after initiating sorafenib treatment on human RCC xenografts.</p></sec><sec><title>Advances in knowledge:</title><p>The quantitative parameters of DCE-MRI and DWI may offer the potential for assessing early therapeutic response to sorafenib in clinical trials.</p></sec></abstract><counts><fig-count count="2"/><table-count count="2"/><ref-count count="32"/><page-count count="7"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>